

Attorney Docket No.: UT-0030  
Inventors: Rao et al.  
Serial No.: 09/736,728  
Filing Date: December 14, 2000  
Page 2

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claims 1-12 (canceled)

Claim 13 (currently amended): A method of obtaining glial cells comprising:

(a) ~~providing isolating~~ glial restricted precursor cells ~~from central nervous system tissue by negative immunoselection of E-NCAM positive cells followed by positive immunoselection with an A2B5 antibody, said glial restricted precursor cells being which are immunonegative for PDGF- $\alpha$  receptor, and PDGF- $\beta$  receptors receptor, and Ran-2 antigen, not labeled with R24 anti-GD3 antibody, and immunopositive for which express A2B5 antigen and which are isolated by positive immunoselection with an A2B5 antibody; and~~

(b) plating the said isolated glial restricted precursor cells ~~provided in of~~ step (a) under differentiating conditions, thereby causing the said isolated glial restricted precursor cells expressing ~~A2B5 antigen which are immunonegative for PDGF- $\alpha$  and PDGF- $\beta$~~  to differentiate into glial cells.

Claim 14 (original): The method of claim 13 wherein said differentiating conditions comprise addition to growth medium of

Attorney Docket No.: UT-0030  
Inventors: Rao et al.  
Serial No.: 09/736,728  
Filing Date: December 14, 2000  
Page 3

an effective amount of a factor that promotes differentiation into non-process bearing A2B5<sup>+</sup>GFAP<sup>+</sup> astrocytes and said glial cells are A2B5<sup>+</sup>GFAP<sup>+</sup> astrocytes.

Claim 15 (original): The method of claim 14 wherein said factor that promotes differentiation into non-process bearing A2B5<sup>+</sup>GFAP<sup>+</sup> astrocytes comprises fetal calf serum.

Claim 16 (original): The method of claim 13 wherein said differentiating conditions comprise addition to growth medium of an effective amount of a factor that promotes differentiation into process bearing A2B5<sup>+</sup>GFAP<sup>+</sup> astrocytes and said glial cells are A2B5<sup>+</sup>GFAP<sup>+</sup> astrocytes.

Claim 17 (original): The method of claim 16 wherein said factor that promotes differentiation into process bearing A2B5<sup>+</sup>GFAP<sup>+</sup> astrocytes comprises ciliary neurotrophic factor and basic fibroblast growth factor.

Claim 18 (original): The method of claim 13 wherein said differentiating conditions comprise addition to growth medium of an effective amount of a factor that promotes differentiation into oligodendrocytes and said glial cells are oligodendrocytes.

Claim 19 (original): The method of claim 18 wherein said factor that promotes differentiation into oligodendrocytes comprises platelet-derived growth factor and thyroid hormone

Attorney Docket No.: UT-0030  
Inventors: Rao et al.  
Serial No.: 09/736,728  
Filing Date: December 14, 2000  
Page 4

(T3).

Claims 20-48 (canceled)

Claim 49 (currently amended): A method for continuously propagating glial restricted precursor cells immunonegative for PDGF- $\alpha$  receptor, and PDGF- $\beta$  receptor, and Ran-2 antigen, not labeled with R24 anti-GD3 antibody, and immunopositive for which express A2B5 antigen comprising the steps of:

(a) providing said isolating glial restricted precursor cells from central nervous system tissue by negative immunoselection of E-NCAM positive cells followed by positive immunoselection with an A2B5 antibody, said glial restricted precursor cells being which are immunonegative for PDGF- $\alpha$  receptor, and PDGF- $\beta$  receptors receptor, and Ran-2 antigen, not labeled with R24 anti-GD3 antibody, and immunopositive for which express A2B5 antigen and which are isolated by positive immunoselection with an A2B5 antibody; and

(b) culturing said isolated glial restricted precursor cells provided in of step (a) in vitro in the presence of minimal essential salts and effective amounts of platelet derived growth factor and fibroblast growth factor.